Skip to main content
Access Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

From
To
  • Default content image

    LRRK2 Detection in PBMC Consortium

    The “LRRK2 Detection in PBMC Consortium” is a pre-competitive collaboration between MJFF and select industry partners with the goal of optimizing the measurement of pLRRK2 in human PBMCs. MJFF…

  • Default content image

    Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents

    Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting approximately one-percent of the population over the age of sixty. Although many animal models have been…

  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Parkin/PINK1 and LRRK2- and PINK1-Related Rab Molecular Biology

    A field-wide challenge in Parkinson’s disease (PD) research is a general lack of availability for high-quality, reproducible, and readily accessible preclinical research tools. To address these…

  • Default content image

    The Michael J. Fox Foundation’s Efforts to Generate, Characterize, and Promote the Use of a Variety of Preclinical Models of Parkinson’s Disease

    Preclinical models are a necessary tool for investigating the pathogenesis and potential therapeutic strategies for diseases like Parkinson’s disease (PD). As the precise etiology of PD is currently…

  • Default content image

    User's guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations

    This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids…

  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Alpha-Synuclein Research Tools for Molecular Biology

    Mutations in the gene SNCA that encodes the protein alpha-synuclein as well as postmortem pathological studies strongly implicate a general role for alpha-synuclein in Parkinson’s disease (PD)…

  • Default content image

    Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors

    Genta Ito, Kristina Katsemonova, Francesca Tonelli, Pawel Lis, Marco Baptista, Natalia Shpiro, Graham Duddy, Steve Wilson, Wing-Lok Ho, Shu-Leong Ho, Alastair D Reith, Dario R Alessi Autosomal…

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

From
To

No results were found.

Michael J. Fox Foundation publications supported through our OAP program.

We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease. 

Request open access coverage funds for your MJFF project here

From
To
  • Default content image

    Beta2-Adrenoreceptor Agonist Clenbuterol Produces Transient Decreases in Alpha-Synuclein mRNA but No Long-term Reduction in Protein

    β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson's disease (PD) and are hypothesized to decrease expression of both alpha-synuclein mRNA (Snca) and…

  • Default content image

    Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function

    Genetic and neuropathological evidence strongly implicates aberrant forms of α-synuclein in neurodegeneration. Antibodies specific for α-synuclein phosphorylated at serine 129 (pS129) are selective…

  • Default content image

    Lipid pathway dysfunction is prevalent in patients with Parkinson's disease

    Many genetic risk factors for Parkinson's disease have lipid-related functions and lipid-modulating drugs such as statins may be protective against Parkinson's disease. Moreover, the hallmark…

  • Default content image

    The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models

    Abstract Heterozygous mutations in the GBA1 gene-encoding lysosomal glucocerebrosidase (GCase)--are the most common genetic risk factor for Parkinson's disease (PD). Experimental evidence suggests a…

  • Default content image

    Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease

    Abstract Background: There is growing interest in health-related quality of life (HRQOL) as a comprehensive view of the patient's well-being, guiding concept for the treating clinician, and…

  • Default content image

    Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson's disease (randomized controlled trial)

    Objective: To evaluate the effectiveness of personalized and home-based speech therapy on quality of life, intelligibility, and social participation for people with Parkinson's disease (PD) who have…

  • Default content image

    Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages

    Abstract Leucine-rich-repeat kinase 2 (LRRK2), a potential therapeutic target for the treatment of Parkinson's disease (PD), is highly expressed in monocytes and macrophages and may play a role in…

Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.